BACKGROUND: Approximately 15 700 invasive methicillin-resistant Staphylococcus aureus (MRSA) infections occurred in US dialysis patients in 2010. Frequent hospital visits and prolonged bloodstream access, especially via central venous catheters (CVCs), are risk factors among hemodialysis patients. We describe the epidemiology of and recent trends in invasive MRSA infections among dialysis patients. METHODS: We analyzed population-based data from 9 US metropolitan areas from 2005 to 2011. Cases were defined as MRSA isolated from a normally sterile body site in a surveillance area resident who received dialysis, and were classified as hospital-onset (HO; culture collected >3 days after hospital admission) or healthcare-associated community-onset (HACO; all others). Incidence was calculated using denominators from the US Renal Data System. Temporal trends in incidence and national estimates were calculated controlling for age, sex, and race. RESULTS: From 2005 to 2011, 7489 cases were identified; 85.7% were HACO infections, and 93.2% were bloodstream infections. Incidence of invasive MRSA infections decreased from 6.5 to 4.2 per 100 dialysis patients (annual decrease, 7.3%) with annual decreases of 6.7% for HACO and 10.5% for HO cases. Among cases identified during 2009-2011, 70% of patients were hospitalized in the year prior to infection. Among hemodialysis cases, 60.4% of patients were dialyzed through a CVC. The 2011 national estimated number of MRSA infections was 15 169. CONCLUSIONS: There has been a substantial decrease in invasive MRSA infection incidence among dialysis patients. Most cases had previous hospitalizations, suggesting that efforts to control MRSA in hospitals might have contributed to the declines. Infection prevention measures should include improved vascular access and CVC care.
BACKGROUND: Approximately 15 700 invasive methicillin-resistant Staphylococcus aureus (MRSA) infections occurred in US dialysis patients in 2010. Frequent hospital visits and prolonged bloodstream access, especially via central venous catheters (CVCs), are risk factors among hemodialysis patients. We describe the epidemiology of and recent trends in invasive MRSA infections among dialysis patients. METHODS: We analyzed population-based data from 9 US metropolitan areas from 2005 to 2011. Cases were defined as MRSA isolated from a normally sterile body site in a surveillance area resident who received dialysis, and were classified as hospital-onset (HO; culture collected >3 days after hospital admission) or healthcare-associated community-onset (HACO; all others). Incidence was calculated using denominators from the US Renal Data System. Temporal trends in incidence and national estimates were calculated controlling for age, sex, and race. RESULTS: From 2005 to 2011, 7489 cases were identified; 85.7% were HACO infections, and 93.2% were bloodstream infections. Incidence of invasive MRSA infections decreased from 6.5 to 4.2 per 100 dialysis patients (annual decrease, 7.3%) with annual decreases of 6.7% for HACO and 10.5% for HO cases. Among cases identified during 2009-2011, 70% of patients were hospitalized in the year prior to infection. Among hemodialysis cases, 60.4% of patients were dialyzed through a CVC. The 2011 national estimated number of MRSA infections was 15 169. CONCLUSIONS: There has been a substantial decrease in invasive MRSA infection incidence among dialysis patients. Most cases had previous hospitalizations, suggesting that efforts to control MRSA in hospitals might have contributed to the declines. Infection prevention measures should include improved vascular access and CVC care.
Entities:
Keywords:
dialysis; invasive MRSA; methicillin-resistant S. aureus
Authors: Manoch Rattanasompattikul; Usama Feroze; Miklos Z Molnar; Ramanath Dukkipati; Csaba P Kovesdy; Allen R Nissenson; Keith C Norris; Joel D Kopple; Kamyar Kalantar-Zadeh Journal: Int Urol Nephrol Date: 2011-11-30 Impact factor: 2.370
Authors: Ronald L Pisoni; Eric W Young; Dawn M Dykstra; Roger N Greenwood; Erwin Hecking; Brenda Gillespie; Robert A Wolfe; David A Goodkin; Philip J Held Journal: Kidney Int Date: 2002-01 Impact factor: 10.612
Authors: E Yoko Furuya; Andrew Dick; Eli N Perencevich; Monika Pogorzelska; Donald Goldmann; Patricia W Stone Journal: PLoS One Date: 2011-01-18 Impact factor: 3.240
Authors: Ioannis M Zacharioudakis; Fainareti N Zervou; Panayiotis D Ziakas; Eleftherios Mylonakis Journal: J Am Soc Nephrol Date: 2014-03-20 Impact factor: 10.121
Authors: Duc B Nguyen; Alicia Shugart; Christi Lines; Ami B Shah; Jonathan Edwards; Daniel Pollock; Dawn Sievert; Priti R Patel Journal: Clin J Am Soc Nephrol Date: 2017-06-29 Impact factor: 8.237
Authors: Shu-Hua Wang; Lisa Hines; Joany van Balen; José R Mediavilla; Xueliang Pan; Armando E Hoet; Barry N Kreiswirth; Preeti Pancholi; Kurt B Stevenson Journal: J Clin Microbiol Date: 2015-03-04 Impact factor: 5.948
Authors: Kyle J Popovich; Evan S Snitkin; Bala Hota; Stefan J Green; Ali Pirani; Alla Aroutcheva; Robert A Weinstein Journal: J Infect Dis Date: 2017-06-01 Impact factor: 5.226
Authors: Tebeb Gebretsadik; William O Cooper; Lijing Ouyang; Judy Thibadeau; Tiffanie Markus; Jessica Cook; Sarah Tesfaye; Edward F Mitchel; Kimberly Newsome; Kecia N Carroll Journal: Disabil Health J Date: 2020-04-21 Impact factor: 2.554
Authors: Kelly A Jackson; Runa H Gokhale; Joelle Nadle; Susan M Ray; Ghinwa Dumyati; William Schaffner; David C Ham; Shelley S Magill; Ruth Lynfield; Isaac See Journal: Clin Infect Dis Date: 2020-03-03 Impact factor: 9.079
Authors: Kyle J Popovich; Stefan J Green; Koh Okamoto; Yoona Rhee; Mary K Hayden; Michael Schoeny; Evan S Snitkin; Robert A Weinstein Journal: Clin Infect Dis Date: 2021-06-01 Impact factor: 20.999